Sanofi Receives FDA Approval for MenQuadfi Meningococcal Vaccine in Infants as Young as 6 Weeks

Gelonghui May 27 | French pharmaceutical company Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved its meningococcal vaccine for use in infants as young as six weeks old. The vaccine, branded as MenQuadfi, was previously approved for individuals aged two years and older to prevent against the four most common strains of meningococcal bacteria.